Lv433
510 积分 2023-11-16 加入
Trends in List and Net Prices of Self-administered Systemic Psoriasis Therapies Manufactured by US-Based Pharmaceutical Companies
2天前
已完结
Bispecific T cell engager therapy for refractory rheumatoid arthritis
12天前
已完结
Autoimmune disease is the next frontier for CAR T cell therapy
12天前
已完结
BCMA-Targeted T-Cell–Engager Therapy for Autoimmune Disease
12天前
已完结
TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis
20天前
已完结
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study
24天前
已完结
Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
28天前
已完结
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
28天前
已完结
GALAXI 2 & 3: Guselkumab proves efficacy in Crohn’s disease
28天前
已关闭
Risankizumab for Ulcerative Colitis
30天前
已完结
皖公网安备34019202002308
